Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...
Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise o...
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA...
Emergent BioSolutions Inc. announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Glo...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endo...
Thermo Fisher Scientific Inc., the world leader in serving science, announced a strategic collaboration with SHL Medical, a leading provider of advance...
Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has ann...
HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&...
SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity,...
Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex c...
Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
Imaginostics, Inc. announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions ...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
© 2026 Biopharma Boardroom. All Rights Reserved.
